Roche Launches $5.7B Hostile Bid For Illumina

Law360, New York (January 25, 2012, 1:42 PM EST) -- Swiss drug maker Roche Holding Ltd. on Wednesday made a $5.7 billion hostile bid for gene sequencing company Illumina Inc., saying it had gotten the cold shoulder from Illumina's board.

The proposed deal would give Roche a foothold in the developing field of gene technology, which could lead to a quicker and more accurate process for developing drugs targeted at specific problem.

Roche's chairman Franz Humer said in a letter to Illumina CEO Jay Flatley that the Illumina board of directors' stated lack of interest in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.